Home > Publications Database > Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex. > print

001     280222
005     20250824001743.0
024 7 _ |a 10.1038/s41593-025-02000-6
|2 doi
024 7 _ |a pmid:40670684
|2 pmid
024 7 _ |a pmc:PMC12321570
|2 pmc
024 7 _ |a 1097-6256
|2 ISSN
024 7 _ |a 1546-1726
|2 ISSN
024 7 _ |a altmetric:179433936
|2 altmetric
037 _ _ |a DZNE-2025-00900
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ossenkoppele, Rik
|0 0000-0003-1584-7477
|b 0
245 _ _ |a Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex.
260 _ _ |a New York, NY
|c 2025
|b Nature America
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1754897835_31918
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Tau positron emission tomography (PET) imaging allows in vivo detection of tau proteinopathy in Alzheimer's disease, which is associated with neurodegeneration and cognitive decline. Understanding how demographic, clinical and genetic factors relate to tau PET positivity will facilitate its use for clinical practice and research. Here we conducted an analysis of 42 cohorts worldwide (N = 12,048), including 7,394 cognitively unimpaired (CU) participants, 2,177 participants with mild cognitive impairment (MCI) and 2,477 participants with dementia. We found that from age 60 years to 80 years, tau PET positivity in a temporal composite region increased from 1.1% to 4.4% among CU amyloid-β (Aβ)-negative participants and from 17.4% to 22.2% among CU Aβ-positive participants. Across the same age span, tau PET positivity decreased from 68.0% to 52.9% in participants with MCI and from 91.5% to 74.6% in participants with dementia. Age, Aβ status, APOE ε4 carriership and female sex were all associated with a higher prevalence of tau PET positivity across groups. APOE ε4 carriership in CU individuals lowered the age at onset of both Aβ positivity and tau positivity by decades. Finally, we replicated these associations in an independent autopsy dataset (N = 5,072 from 3 cohorts).
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Apolipoproteins E
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: genetics
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: genetics
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: metabolism
|2 MeSH
650 _ 2 |a Apolipoproteins E: genetics
|2 MeSH
650 _ 2 |a Genotype
|2 MeSH
650 _ 2 |a Age Factors
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Sex Factors
|2 MeSH
700 1 _ |a Coomans, Emma M
|b 1
700 1 _ |a Apostolova, Liana G
|b 2
700 1 _ |a Baker, Suzanne L
|b 3
700 1 _ |a Barthel, Henryk
|b 4
700 1 _ |a Beach, Thomas G
|b 5
700 1 _ |a Benzinger, Tammy L S
|0 0000-0002-8114-0552
|b 6
700 1 _ |a Betthauser, Tobey
|0 0000-0001-8856-1352
|b 7
700 1 _ |a Bischof, Gérard N
|b 8
700 1 _ |a Bottlaender, Michel
|0 0000-0002-2890-3653
|b 9
700 1 _ |a Bourgeat, Pierick
|0 0000-0002-2605-4766
|b 10
700 1 _ |a den Braber, Anouk
|b 11
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 12
700 1 _ |a Brickman, Adam M
|0 0000-0002-5125-8226
|b 13
700 1 _ |a Cash, David M
|0 0000-0001-7833-616X
|b 14
700 1 _ |a Carrillo, Maria C
|b 15
700 1 _ |a Coath, William
|b 16
700 1 _ |a Christian, Bradley T
|0 0000-0002-9653-559X
|b 17
700 1 _ |a Dickerson, Brad C
|0 0000-0002-5958-3445
|b 18
700 1 _ |a Dore, Vincent
|0 0000-0002-8051-0558
|b 19
700 1 _ |a Drzezga, Alexander
|0 P:(DE-2719)2811239
|b 20
700 1 _ |a Feizpour, Azadeh
|0 0000-0003-0826-4011
|b 21
700 1 _ |a van der Flier, Wiesje M
|0 0000-0001-8766-6224
|b 22
700 1 _ |a Franzmeier, Nicolai
|0 0000-0001-9736-2283
|b 23
700 1 _ |a Frisoni, Giovanni B
|b 24
700 1 _ |a Garibotto, Valentina
|b 25
700 1 _ |a van de Giessen, Elsmarieke
|0 0000-0001-9956-4233
|b 26
700 1 _ |a Domingo-Gispert, Juan
|b 27
700 1 _ |a Gnoerich, Johannes
|0 P:(DE-2719)9001652
|b 28
|u dzne
700 1 _ |a Gu, Yuna
|b 29
700 1 _ |a Guan, Yihui
|b 30
700 1 _ |a Hanseeuw, Bernard J
|b 31
700 1 _ |a Harrison, Theresa M
|b 32
700 1 _ |a Jack, Clifford R
|0 0000-0001-7916-622X
|b 33
700 1 _ |a Jaeger, Elena
|0 0009-0007-9387-3175
|b 34
700 1 _ |a Jagust, William J
|0 0000-0002-4458-113X
|b 35
700 1 _ |a Jansen, Willemijn J
|b 36
700 1 _ |a La Joie, Renaud
|0 0000-0003-2581-8100
|b 37
700 1 _ |a Johnson, Keith A
|b 38
700 1 _ |a Johnson, Sterling C
|0 0000-0002-8501-545X
|b 39
700 1 _ |a Kennedy, Ian A
|b 40
700 1 _ |a Kim, Jun Pyo
|0 0000-0003-4376-3107
|b 41
700 1 _ |a van Laere, Koen
|0 0000-0001-5200-7245
|b 42
700 1 _ |a Lagarde, Julien
|0 0000-0002-2018-261X
|b 43
700 1 _ |a Lao, Patrick
|b 44
700 1 _ |a Luchsinger, José A
|b 45
700 1 _ |a Kern, Silke
|b 46
700 1 _ |a Kreisl, William C
|b 47
700 1 _ |a Malotaux, Vincent
|b 48
700 1 _ |a Malpetti, Maura
|0 0000-0001-8923-9656
|b 49
700 1 _ |a Manly, Jennifer J
|b 50
700 1 _ |a Mao, Xiaoxie
|b 51
700 1 _ |a Mattsson-Carlgren, Niklas
|0 0000-0002-8885-7724
|b 52
700 1 _ |a Aging, Mayo Clinic Study on
|b 53
|e Collaboration Author
700 1 _ |a Messerschmidt, Konstantin
|b 54
700 1 _ |a Minguillon, Carolina
|b 55
700 1 _ |a Mormino, Elizabeth M
|b 56
700 1 _ |a O'Brien, John T
|0 0000-0002-0837-5080
|b 57
700 1 _ |a Palmqvist, Sebastian
|0 0000-0002-9267-1930
|b 58
700 1 _ |a Peretti, Debora E
|0 0000-0002-3033-8817
|b 59
700 1 _ |a Petersen, Ron C
|0 0000-0002-8178-6601
|b 60
700 1 _ |a Pijnenburg, Yolande A L
|b 61
700 1 _ |a Pontecorvo, Michael J
|b 62
700 1 _ |a Poirier, Judes
|0 0000-0002-8018-4545
|b 63
700 1 _ |a Group, PREVENT-AD Research
|b 64
|e Collaboration Author
700 1 _ |a Rabinovici, Gil D
|0 0000-0002-3626-4265
|b 65
700 1 _ |a Rahmouni, Nesrine
|b 66
700 1 _ |a Risacher, Shannon L
|0 0000-0002-3304-7943
|b 67
700 1 _ |a Rosa-Neto, Pedro
|0 0000-0001-9116-1376
|b 68
700 1 _ |a Rosen, Howard
|b 69
700 1 _ |a Rowe, Christopher C
|0 0000-0003-3910-2453
|b 70
700 1 _ |a Rowe, James B
|0 0000-0001-7216-8679
|b 71
700 1 _ |a Rullmann, Michael
|b 72
700 1 _ |a Salman, Yasmine
|0 0000-0002-8564-5136
|b 73
700 1 _ |a Sarazin, Marie
|b 74
700 1 _ |a Saykin, Andrew J
|0 0000-0002-1376-8532
|b 75
700 1 _ |a Schneider, Julie A
|0 0000-0002-9482-1752
|b 76
700 1 _ |a Schöll, Michael
|0 0000-0001-7800-1781
|b 77
700 1 _ |a Schott, Jonathan M
|0 0000-0003-2059-024X
|b 78
700 1 _ |a Seo, Sang Won
|b 79
700 1 _ |a Serrano, Geidy E
|b 80
700 1 _ |a Shcherbinin, Sergey
|b 81
700 1 _ |a Shekari, Mahnaz
|b 82
700 1 _ |a Skoog, Ingmar
|b 83
700 1 _ |a Smith, Ruben
|0 0000-0001-7147-0112
|b 84
700 1 _ |a Sperling, Reisa A
|b 85
700 1 _ |a Spruyt, Laure
|0 0000-0002-0618-5005
|b 86
700 1 _ |a Stomrud, Erik
|b 87
700 1 _ |a Strandberg, Olof
|b 88
700 1 _ |a Therriault, Joseph
|b 89
700 1 _ |a Xie, Fang
|0 0000-0003-2667-281X
|b 90
700 1 _ |a Vandenberghe, Rik
|0 0000-0001-6237-2502
|b 91
700 1 _ |a Villemagne, Victor L
|b 92
700 1 _ |a Villeneuve, Sylvia
|0 0000-0003-2338-0467
|b 93
700 1 _ |a Visser, Pieter Jelle
|0 0000-0001-8008-9727
|b 94
700 1 _ |a Vossler, Hillary
|0 0009-0007-8693-1939
|b 95
700 1 _ |a Young, Christina B
|b 96
700 1 _ |a Groot, Colin
|b 97
700 1 _ |a Hansson, Oskar
|0 0000-0001-8467-7286
|b 98
700 1 _ |a Petersen, Ron C
|b 99
|e Contributor
773 _ _ |a 10.1038/s41593-025-02000-6
|g Vol. 28, no. 8, p. 1610 - 1621
|0 PERI:(DE-600)1494955-6
|n 8
|p 1610 - 1621
|t Nature neuroscience
|v 28
|y 2025
|x 1097-6256
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/280222/files/DZNE-2025-00900.pdf
856 4 _ |u https://pub.dzne.de/record/280222/files/DZNE-2025-00900%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/280222/files/DZNE-2025-00900%20SUP2.pdf
856 4 _ |u https://pub.dzne.de/record/280222/files/DZNE-2025-00900%20SUP1.pdf?subformat=pdfa
|x pdfa
856 4 _ |u https://pub.dzne.de/record/280222/files/DZNE-2025-00900%20SUP2.pdf?subformat=pdfa
|x pdfa
856 4 _ |u https://pub.dzne.de/record/280222/files/DZNE-2025-00900.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:280222
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9001539
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2811239
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 28
|6 P:(DE-2719)9001652
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT NEUROSCI : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-07
915 _ _ |a DEAL Nature
|0 StatID:(DE-HGF)3003
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-07
915 _ _ |a IF >= 25
|0 StatID:(DE-HGF)9925
|2 StatID
|b NAT NEUROSCI : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1011202
|k AG Boecker
|l Positron Emissions Tomography (PET)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1011202
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21